Cutaneous reactions after COVID‐19 vaccination in Turkey: A multicenter study. (19th July 2022)

• Record Type: Journal Article
• Authors: Cebeci Kahraman, Filiz; Savaş Erdoğan, Sevil; Aktaş, Nurhan Döner; Albayrak, Hülya; Türkmen, Dursun; Borlu, Murat; Arıca, Deniz Aksu; Demirbaş, Abdullah; Akbayrak, Atiye; Polat Ekinci, Algün; Gökçek, Gözde Emel; Çelik, Hilal Ayvaz; Taşolar, Mustafa Kaan; An, İsa; Temiz, Selami Aykut; Hazinedar, Emel; Ayhan, Erhan; Hızlı, Pelin; Solak, Eda Öksüm; Kılıç, Arzu; Yılmaz, Ertan
• Is Part Of: Journal of cosmetic dermatology. Volume 21:Number 9(2022)
• Page Start: 3692
• Page End: 3703
• Publication Date: 2022-07-19
• Subjects: Skin -- Diseases -- Treatment -- Periodicals; Lasers in surgery -- Periodicals; Skin -- Pathophysiology -- Periodicals; Surgery, Plastic -- Periodicals; 616.5
• DOI: 10.1111/jocd.15209
• Languages: English
• ISSNs: 1473-2130

Abstract

Abstract: Objectives: In this study covering all of Turkey, we aimed to define cutaneous and systemic adverse reactions in our patient population after COVID‐19 vaccination with the Sinovac/CoronaVac (inactivated SARS‐CoV‐2) and Pfizer/BioNTech (BNT162b2) vaccines. Methods: This prospective, cross‐sectional study included individuals presenting to the dermatology or emergency outpatient clinics of a total of 19 centers after having been vaccinated with the COVID‐19 vaccines. Systemic, local injection site, and non‐local cutaneous reactions after vaccination were identified, and their rates were determined. Results: Of the 2290 individuals vaccinated between April 15 and July 15, 2021, 2097 (91.6%) received the CoronaVac vaccine and 183 (8%) BioNTech. Systemic reactions were observed at a rate of 31.0% after the first CoronaVac dose, 31.1% after the second CoronaVac dose, 46.4% after the first BioNTech dose, and 46.2% after the second BioNTech dose. Local injection site reactions were detected at a rate of 35.6% after the first CoronaVac dose, 35.7% after the second CoronaVac dose, 86.9% after the first BioNTech dose, and 94.1% after the second BioNTech dose. A total of 133 non‐local cutaneous reactions were identified after the CoronaVac vaccine (2.9% after the first dose and 3.5% after the second dose), with the most common being urticaria/angioedema, pityriasis rosea, herpes zoster, and maculopapular rash. After BioNTech, 39 non‐local cutaneous reactions were observed to have developed (24.8% after the first dose and 5% after the second dose), and the most common were herpes zoster, delayed large local reaction, pityriasis rosea, and urticaria/angioedema in order of frequency. Existing autoimmune diseases were triggered in 2.1% of the patients vaccinated with CoronaVac and 8.2% of those vaccinated with BioNTech. Conclusions: There are no comprehensive data on cutaneous adverse reactions specific to the CoronaVac vaccine. We determined the frequency of adverse reactions from the dermatologist's point of view after CoronaVac and BioNTech vaccination and identified a wide spectrum of non‐local cutaneous reactions. Our data show that CoronaVac is associated with less harmful reactions while BioNTech may result in more serious reactions, such as herpes zoster, anaphylaxis, and triggering of autoimmunity. However, most of these reactions were self‐limiting or required little therapeutic intervention.